Paul Capital invests in Indian drugmaker

The US-based firm will use its royalty fund to help the company develop a US portfolio of dermatology drugs.

3 January 2013•2 mins read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.